Anavex Life Sciences Corp (STU:12X1)
€ 8.512 1.462 (20.74%) Market Cap: 724.16 Mil Enterprise Value: 594.65 Mil PE Ratio: 0 PB Ratio: 5.98 GF Score: 40/100

Anavex Life Sciences Corp to Discuss ANAVEX®3-71 Phase 1 Top Line Data Call Transcript

Jan 10, 2022 / 01:30PM GMT
Release Date Price: €13.3 (-3.62%)
Clint Tomlinson
Anavex Life Sciences Corp. - VP of Corporate

Thank you, and good morning, everyone. Welcome to the Anavex Life Sciences ANAVEX-3-71 Phase I top line data conference call. My name is Clint Tomlinson, and I will be your host for today's call. (Operator Instructions)

During this session, if you would like to speak and ask a question, please use the raise your hand button on the bottom. However, if you prefer to leave a question in writing, please use the Q&A button on the bottom right. Please note that this conference is being recorded.

The call will be available for replay on Anavex's website at www.anavex.com. With us today is Dr. Christopher Missling, President and Chief Executive Officer; and Dr. Ed Hammond, Chief Medical Officer.

Before we begin, please note that during the conference call, the company will make some projections and forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot